This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the selected BMS-986435 tablet formulation will also be evaluated.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum observed concentration (Cmax)
Timeframe: Up to Day 28
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Timeframe: Up to Day 28
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Timeframe: Up to Day 28
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com